Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 6, 2024. 

NeurologyLive® Friday 5 — September 6, 2024

Treatment with DYNE-251 revealed dose dependent exon skipping and dystrophin expression as well as improvement in multiple functional end points in both cohorts of the phase 1/2 DELIVER trial.

DYNE-251 Increases Dystrophin Level Expression in Phase 1/2 DELIVER Trial of Duchenne

Tanya, a patient who lost her mobility due to undiagnosed spinal issues, discussed her life-saving surgery for spinal meningioma, and the complex surgical process she underwent to regain her strength.

Treating Rare Cases of Spinal Meningioma Using Complex Surgical Tactics

Videos

The global head of neurology development at Sanofi provided insight on how tolebrutinib may overcome the challenges of treating non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Therapeutic Potential of BTK Inhibitor Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis: Erik Wallstroem, MD, PhD

, has been with the team since October 2019. Follow him on Twitter 

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Imad Najm, MD, PhD. [LISTEN TIME: 22 minutes]

Episode 123: Previewing Cleveland Clinic's Epilepsy Summit

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided commentary on the future outlook of gene therapies for patients with epilepsy, and some of the knowledge and technical barriers clinicians currently face. [WATCH TIME: 5 minutes]

Promise and Potential Challenges With Gene Therapy in Epilepsy: Imad Najm, MD

The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided clinical perspective on some of the improvements in the everyday life and care of patients with spinal muscular atrophy.

NeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and Treatments

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAIC 2024

FEATURE: Parkinson's Secondary Symptoms

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Presentations at the American College of Cardiology’s Annual Scientific Sessions included potential heart issues related to Zika infection, risk of stroke and heart failure with cannabis use, and neurocognitive impairment with PCSK9 variants.

Slideshows

Research includes a possible link between Zika & CV issues, CV effects of cannabis use, and neurocognitive impairment with PCSK9 variants.   

Clinical

ACC 2017: CV Risk Factors